Literature DB >> 10444360

Costimulatory markers in muscle of patients with idiopathic inflammatory myopathies and in cultured muscle cells.

K Nagaraju1, N Raben, M L Villalba, C Danning, L A Loeffler, E Lee, N Tresser, A Abati, P Fetsch, P H Plotz.   

Abstract

In an attempt to understand the mechanisms of cell injury in the inflammatory myopathies, we analyzed the expression of costimulatory molecules, CTLA4, CD28, CD86, CD40, and CD154 as well as HLA class I, HLA class II, and ICAM-I in normal muscle and in muscle biopsies from patients with polymyositis (PM) or dermatomyositis (DM). By immunohistochemical staining, DM and PM biopsies showed the presence of CTLA4, CD28, CD86, and CD40 on inflammatory cells. More strikingly, however, low levels of CTLA4 and CD28 were observed on muscle cells. The expression of CTLA4 and CD28 on nonlymphoid cells has not been previously reported. These unexpected findings were confirmed in cultured normal human myoblasts: various proinflammatory cytokines induced the expression of CTLA4 and CD28 on normal human muscle cells. The sequences of the cDNAs were found to be identical to the sequences for these molecules in T cells. The data suggest a novel complexity in the network of cellular interactions between the infiltrated immune cells and the muscle cells in which the normal relationship between infiltrating inflammatory cells and target tissue is under a previously unrecognized set of controls.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10444360     DOI: 10.1006/clim.1999.4743

Source DB:  PubMed          Journal:  Clin Immunol        ISSN: 1521-6616            Impact factor:   3.969


  24 in total

Review 1.  Treatment of inflammatory myopathy: emerging therapies and therapeutic targets.

Authors:  Siamak Moghadam-Kia; Rohit Aggarwal; Chester V Oddis
Journal:  Expert Rev Clin Immunol       Date:  2015-08-27       Impact factor: 4.473

Review 2.  Immunotherapy and hypophysitis: clinical presentation, treatment, and biologic insights.

Authors:  Alexander Faje
Journal:  Pituitary       Date:  2016-02       Impact factor: 4.107

3.  Abatacept and sodium thiosulfate for treatment of recalcitrant juvenile dermatomyositis complicated by ulceration and calcinosis.

Authors:  Bita Arabshahi; Robert A Silverman; Olcay Y Jones; Lisa G Rider
Journal:  J Pediatr       Date:  2012-01-13       Impact factor: 4.406

4.  Mechanisms of cell-mediated myocytotoxicity in the peripheral blood of patients with inflammatory myopathies.

Authors:  I Bank; A F Miranda; L Chess
Journal:  J Clin Immunol       Date:  2001-09       Impact factor: 8.317

Review 5.  Treatment of refractory polymyositis and dermatomyositis.

Authors:  Steven R Ytterberg
Journal:  Curr Rheumatol Rep       Date:  2006-06       Impact factor: 4.592

6.  Dysferlin deficiency enhances monocyte phagocytosis: a model for the inflammatory onset of limb-girdle muscular dystrophy 2B.

Authors:  Kanneboyina Nagaraju; Rashmi Rawat; Edina Veszelovszky; Rachana Thapliyal; Akanchha Kesari; Susan Sparks; Nina Raben; Paul Plotz; Eric P Hoffman
Journal:  Am J Pathol       Date:  2008-02-14       Impact factor: 4.307

7.  Critical contribution of CD28-CD80/CD86 costimulatory pathway to protection from Trypanosoma cruzi infection.

Authors:  Yasushi Miyahira; Masaharu Katae; Seiki Kobayashi; Tsutomu Takeuchi; Yoshinosuke Fukuchi; Ryo Abe; Ko Okumura; Hideo Yagita; Takashi Aoki
Journal:  Infect Immun       Date:  2003-06       Impact factor: 3.441

Review 8.  Abatacept as a successful therapy for myositis—a case-based review.

Authors:  Anne M Kerola; Markku J Kauppi
Journal:  Clin Rheumatol       Date:  2014-02-04       Impact factor: 2.980

9.  Dysferlin deficiency shows compensatory induction of Rab27A/Slp2a that may contribute to inflammatory onset.

Authors:  Akanchha Kesari; Mitsunori Fukuda; Susan Knoblach; Rumaisa Bashir; Gustavo A Nader; Deepak Rao; Kanneboyina Nagaraju; Eric P Hoffman
Journal:  Am J Pathol       Date:  2008-10-02       Impact factor: 4.307

Review 10.  Advances in the immunopathophysiology of the idiopathic inflammatory myopathies: not as simple as suspected.

Authors:  Gerald J D Hengstman
Journal:  Curr Rheumatol Rep       Date:  2007-08       Impact factor: 4.592

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.